XML 89 R78.htm IDEA: XBRL DOCUMENT
v3.24.3

Segment Reporting - Sales from Products (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2024 | Sep. 30, 2023 | Sep. 30, 2024 | Sep. 30, 2023
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 16,657 | $ 15,962 | $ 48,544 | $ 45,485
Increase in hedge revenue |  |  | 156 | 173
Revenue related to the sale of the marketing rights |  |  | 91 | 118
U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8,736 | 7,715 | 24,089 | 21,393
Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,922 | 8,247 | 24,455 | 24,092
Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 16,430 | 15,663 | 47,838 | 44,789
Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8,714 | 7,615 | 23,980 | 21,258
Operating Segments | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,716 | 8,048 | 23,858 | 23,531
Corporate, Non-Segment |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 227 | 299 | 706 | 696
Corporate, Non-Segment | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 22 | 100 | 109 | 135
Corporate, Non-Segment | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 206 | 199 | 597 | 561
Pharmaceutical | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 14,943 | 14,263 | 43,358 | 40,442
Pharmaceutical | Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8,227 | 7,153 | 22,563 | 19,840
Pharmaceutical | Operating Segments | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,717 | 7,110 | 20,795 | 20,602
Pharmaceutical | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,429 | 6,338 | 21,646 | 18,403
Pharmaceutical | Operating Segments | Keytruda | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4,500 | 3,795 | 13,031 | 11,142
Pharmaceutical | Operating Segments | Keytruda | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2,929 | 2,543 | 8,614 | 7,261
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 337 | 299 | 947 | 884
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 161 | 153 | 449 | 439
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 177 | 146 | 498 | 445
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 251 | 260 | 755 | 734
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 173 | 160 | 523 | 476
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 78 | 100 | 233 | 258
Pharmaceutical | Operating Segments | Welireg |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 139 | 54 | 349 | 146
Pharmaceutical | Operating Segments | Welireg | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 127 | 51 | 320 | 141
Pharmaceutical | Operating Segments | Welireg | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 12 | 3 | 29 | 6
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 100 | 52 | 261 | 142
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 82 | 43 | 215 | 108
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 18 | 10 | 45 | 33
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2,306 | 2,585 | 7,032 | 7,015
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,020 | 838 | 2,045 | 1,718
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,285 | 1,746 | 4,988 | 5,297
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 703 | 713 | 1,891 | 1,823
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 572 | 567 | 1,500 | 1,435
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 131 | 146 | 391 | 388
Pharmaceutical | Operating Segments | Vaxneuvance |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 239 | 214 | 647 | 488
Pharmaceutical | Operating Segments | Vaxneuvance | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 137 | 182 | 397 | 423
Pharmaceutical | Operating Segments | Vaxneuvance | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 103 | 33 | 251 | 65
Pharmaceutical | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 193 | 156 | 572 | 584
Pharmaceutical | Operating Segments | RotaTeq | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 131 | 108 | 388 | 381
Pharmaceutical | Operating Segments | RotaTeq | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 62 | 48 | 185 | 203
Pharmaceutical | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 68 | 140 | 188 | 327
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 19 | 42 | 36 | 105
Pharmaceutical | Operating Segments | Pneumovax 23 | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 49 | 98 | 152 | 223
Pharmaceutical | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 420 | 424 | 1,315 | 1,413
Pharmaceutical | Operating Segments | Bridion | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 339 | 265 | 1,020 | 841
Pharmaceutical | Operating Segments | Bridion | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 81 | 159 | 296 | 572
Pharmaceutical | Operating Segments | Prevymis |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 208 | 157 | 570 | 430
Pharmaceutical | Operating Segments | Prevymis | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 101 | 70 | 265 | 186
Pharmaceutical | Operating Segments | Prevymis | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 107 | 87 | 305 | 244
Pharmaceutical | Operating Segments | Dificid |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 96 | 74 | 261 | 215
Pharmaceutical | Operating Segments | Dificid | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 83 | 69 | 231 | 199
Pharmaceutical | Operating Segments | Dificid | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 13 | 5 | 30 | 16
Pharmaceutical | Operating Segments | Zerbaxa |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 64 | 53 | 182 | 157
Pharmaceutical | Operating Segments | Zerbaxa | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 39 | 29 | 106 | 86
Pharmaceutical | Operating Segments | Zerbaxa | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 26 | 24 | 77 | 71
Pharmaceutical | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 41 | 51 | 141 | 167
Pharmaceutical | Operating Segments | Noxafil | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1 | 4 | 9 | 29
Pharmaceutical | Operating Segments | Noxafil | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 40 | 47 | 132 | 138
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 102 | 92 | 306 | 259
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 96 | 96 | 283 | 249
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7 | (4) | 22 | 10
Pharmaceutical | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 72 | 65 | 214 | 189
Pharmaceutical | Operating Segments | Adempas | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Adempas | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 72 | 65 | 214 | 189
Pharmaceutical | Operating Segments | Winrevair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 149 | 0 | 219 | 0
Pharmaceutical | Operating Segments | Winrevair | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 147 | 0 | 216 | 0
Pharmaceutical | Operating Segments | Winrevair | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 3 | 0 | 3 | 0
Pharmaceutical | Operating Segments | Lagevrio |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 383 | 640 | 843 | 1,236
Pharmaceutical | Operating Segments | Lagevrio | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 84 | 0 | 144 | 0
Pharmaceutical | Operating Segments | Lagevrio | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 299 | 640 | 699 | 1,236
Pharmaceutical | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 102 | 119 | 302 | 377
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 54 | 58 | 147 | 165
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 48 | 61 | 155 | 212
Pharmaceutical | Operating Segments | Delstrigo |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 65 | 54 | 180 | 148
Pharmaceutical | Operating Segments | Delstrigo | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 15 | 13 | 42 | 37
Pharmaceutical | Operating Segments | Delstrigo | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 50 | 40 | 139 | 110
Pharmaceutical | Operating Segments | Pifeltro |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 42 | 37 | 123 | 109
Pharmaceutical | Operating Segments | Pifeltro | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 31 | 27 | 86 | 78
Pharmaceutical | Operating Segments | Pifeltro | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 12 | 10 | 37 | 31
Pharmaceutical | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 78 | 58 | 177 | 176
Pharmaceutical | Operating Segments | Belsomra | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 20 | 23 | 53 | 60
Pharmaceutical | Operating Segments | Belsomra | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 58 | 35 | 124 | 117
Pharmaceutical | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 189 | 179 | 545 | 539
Pharmaceutical | Operating Segments | Simponi | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Simponi | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 189 | 179 | 545 | 539
Pharmaceutical | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 41 | 45 | 115 | 144
Pharmaceutical | Operating Segments | Remicade | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Remicade | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 41 | 45 | 115 | 144
Pharmaceutical | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 278 | 581 | 1,102 | 1,642
Pharmaceutical | Operating Segments | Januvia | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 67 | 328 | 428 | 842
Pharmaceutical | Operating Segments | Januvia | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 211 | 252 | 674 | 800
Pharmaceutical | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 204 | 255 | 679 | 937
Pharmaceutical | Operating Segments | Janumet | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 15 | 43 | 70 | 182
Pharmaceutical | Operating Segments | Janumet | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 190 | 211 | 610 | 755
Pharmaceutical | Operating Segments | Other pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 644 | 568 | 1,796 | 1,758
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 213 | 189 | 559 | 518
Pharmaceutical | Operating Segments | Other pharmaceutical | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 426 | 381 | 1,232 | 1,239
Animal Health | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,487 | 1,400 | 4,480 | 4,347
Animal Health | Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 487 | 462 | 1,417 | 1,418
Animal Health | Operating Segments | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 999 | 938 | 3,063 | 2,929
Animal Health | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 886 | 874 | 2,573 | 2,530
Animal Health | Operating Segments | Livestock | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 194 | 205 | 529 | 543
Animal Health | Operating Segments | Livestock | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 692 | 669 | 2,044 | 1,987
Animal Health | Operating Segments | Companion Animal |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 601 | 526 | 1,907 | 1,817
Animal Health | Operating Segments | Companion Animal | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 293 | 257 | 888 | 875
Animal Health | Operating Segments | Companion Animal | Non-US |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 307 | $ 269 | $ 1,019 | $ 942

X
- Definition Increase (Decrease) In Hedge Revenue + References No definition available. + Details
Name: | mrk_IncreaseDecreaseInHedgeRevenue
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_WeliregMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaxneuvanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DificidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_WinrevairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LagevrioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DelstrigoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PifeltroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |